Ascentage Pharma Group International (NASDAQ:AAPG) Shares Up 8.1% – Here’s What Happened

Ascentage Pharma Group International – Unsponsored ADR (NASDAQ:AAPG)’s share price shot up 8.1% during trading on Wednesday . The company traded as high as $19.31 and last traded at $20.07. 368 shares traded hands during mid-day trading, a decline of 90% from the average session volume of 3,727 shares. The stock had previously closed at $18.56.

Wall Street Analyst Weigh In

A number of brokerages recently commented on AAPG. China Intl Cap raised Ascentage Pharma Group International to a “strong-buy” rating in a research report on Monday, April 6th. BTIG Research reaffirmed a “buy” rating and issued a $48.00 target price on shares of Ascentage Pharma Group International in a research report on Monday, April 13th. Finally, Deutsche Bank Aktiengesellschaft began coverage on Ascentage Pharma Group International in a research report on Friday, April 24th. They issued a “buy” rating and a $40.00 target price for the company. Two analysts have rated the stock with a Strong Buy rating and six have given a Buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Buy” and a consensus target price of $46.67.

Ascentage Pharma Group International Stock Performance

The company has a debt-to-equity ratio of 0.57, a quick ratio of 1.77 and a current ratio of 1.79. The company’s fifty day simple moving average is $23.67 and its two-hundred day simple moving average is $26.43.

Ascentage Pharma Group International (NASDAQ:AAPG) last released its quarterly earnings data on Wednesday, March 25th. The company reported ($0.52) earnings per share for the quarter. The business had revenue of $24.72 million for the quarter. On average, equities research analysts anticipate that Ascentage Pharma Group International – Unsponsored ADR will post -1.09 earnings per share for the current year.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the stock. Mirae Asset Global Investments Co. Ltd. bought a new position in shares of Ascentage Pharma Group International in the third quarter valued at approximately $96,000. UBS Group AG lifted its holdings in shares of Ascentage Pharma Group International by 149.4% in the third quarter. UBS Group AG now owns 18,345 shares of the company’s stock valued at $716,000 after purchasing an additional 10,988 shares in the last quarter. Hsbc Holdings PLC purchased a new position in Ascentage Pharma Group International during the second quarter worth about $391,000. Citadel Advisors LLC purchased a new position in Ascentage Pharma Group International during the third quarter worth about $383,000. Finally, XY Capital Ltd boosted its holdings in Ascentage Pharma Group International by 224.2% during the third quarter. XY Capital Ltd now owns 18,120 shares of the company’s stock worth $707,000 after purchasing an additional 12,530 shares during the last quarter.

Ascentage Pharma Group International Company Profile

Ascentage Pharma Group International is a clinical‐stage biopharmaceutical company focused on developing small‐molecule therapeutics that modulate programmed cell death pathways, including the Bcl‐2 family and the MDM2–p53 axis. Its pipeline features orally bioavailable inhibitors such as APG-2575, a selective Bcl-2 inhibitor, and APG-115, a potent MDM2 antagonist, both aimed at reactivating apoptosis in cancer cells across hematologic malignancies and solid tumors.

Founded in 2008 by biotechnology entrepreneur Dr.